Strain Data Sheet

RBRC02574

update : 2024-11-20

Strain Information
Image
BRC No.	RBRC02574
Type	Targeted Mutation
Species	Mus musculus
Strain name	B6;129P2-Phgdh<tm2Bsi>
Former Common name	floxed allele
H-2 Haplotype
ES Cell line	E14 [129P2/OlaHsd]
Background strain
Appearance
Strain development
Strain description
Colony maintenance
References	Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality. Yoshida K, Furuya S, Osuka S, Mitoma J, Shinoda Y, Watanabe M, Azuma N, Tanaka H, Hashikawa T, Itohara S, Hirabayashi Y J. Biol. Chem., 279, 3573-3577 (2004). 14645240

Health Report
Examination Date / Room / Rack	2024/07/22Room:3-CRack:K 2024/04/22Room:3-CRack:K 2024/01/22Room:3-CRack:K 2023/10/23Room:3-CRack:K 2023/07/24Room:3-CRack:K

Gene
Gene Symbol	Gene Name	Chr.	Allele Symbol	Allele Name	Common Names	Promoter	Diseases Related to This Gene
Phgdh	3-phosphoglycerate dehydrogenase	3	Phgdh	targeted mutation 1.2, Shigeki Furuya			Neu-Laxova syndrome 1(MedGEN) PHGDH deficiency(MedGEN)
loxP	phage P1 loxP	3	loxP				Neu-Laxova syndrome 1(MedGEN) PHGDH deficiency(MedGEN)
loxP	phage P1 loxP	3	loxP				Neu-Laxova syndrome 1(MedGEN) PHGDH deficiency(MedGEN)

Phenotype
Annotation by Mammalian phenotyhpe ontology	normal phenotype(MP:0002873)
Detailed phenotype data

Ordering Information
Donor DNA	Phage P1 loxP sites, mouse 3-Phosphoglycerate dehydrogenase (Phgdh)genomic DNA
Research application	Cre/loxP system
Specific Term and Conditions	The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. J. Biol. Chem. 279, 3573-3577 (2004). 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers. 2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSITOR/DEVELOPER. At the same time, the RECIPIENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate. 3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results. 4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not require collaboration, the RECIPIENT agrees to cite the literature(s) designated by the DEPOSITOR/DEVELOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered. 5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER. 6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity.
Depositor	Yoshio Hirabayashi (RIKEN)
Strain Status	Live mice Frozen embryos Frozen sperm
Strain Availability	Cryopreserved sperm (within 1 month) Cryopreserved embryos (within 1 month) Live mouse (1 to 3 months)
Additional Info.	Necessary documents for ordering: Approval form (Japanese / English) Order form (Japanese / English) Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English) Acceptance of responsibility for living modified organism (Japanese / English) Genotyping protocol -PCR-

BRC mice in Publications

Yohei Hayashi, Jintaro Kaneko, Yumi Ito-Matsuoka, Asuka Takehara, Mayuka Funakoshi, So Maezawa, Kenjiro Shirane, Shigeki Furuya, Yasuhisa Matsui Control of epigenomic landscape and development of fetal male germ cells through L-serine metabolism iScience 110702(2024)